Europe's CHMP gives thumbs up to AZ's breast cancer drug after thumbs down from FDA adcomm

Less than a month after an FDA advisory committee voted 6-3 | Less than a month after an FDA advisory committee recommended rejection of AstraZeneca’s novel cancer drug, Europe’s CHMP has blessed Etcamah with a positive opinion. The EMA also has signed off on Novo Nordisk's Wegovy pill.

Raccontata dafiercepharma.comstatnews.comendpoints.news